Diagnosis, Management, and Associated Comorbidities of Polycystic Ovary Syndrome: A Narrative Review.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or original data
PubMed 38779261 · doi:10.7759/cureus.58733
What was done
This narrative review synthesized literature on polycystic ovary syndrome (PCOS), focusing on diagnostic definitions (specifically Rotterdam criteria), pathophysiology, metabolic and reproductive comorbidities, and management strategies in adolescent and reproductive-aged women.
What was found
The abstract reports no original quantitative data or statistical syntheses. It notes the Rotterdam criteria definition (presence of at least two of: oligo-anovulation, hyperandrogenism, and polycystic ovaries defined as ovarian volume > 10 mL and/or 12 or more follicles measuring 2 to 9 mm). It highlights lifestyle changes as first-line therapy and lists emerging pharmacological options including HMG-CoA reductase inhibitors, gliptins, GLP-1 receptor analogues, glitazones, SGLT2 inhibitors, and mucolytic agents.
Why it matters
The review summarizes the shift toward recognizing PCOS as a multifaceted cardiometabolic disorder and outlines diverse pharmacological classes targeting underlying metabolic dysfunctions.
Limits
As a narrative review, it lacks a systematic search strategy, structured inclusion/exclusion criteria, and risk of bias assessment. The abstract reports no original patient data, sample sizes, or effect estimates.